Working… Menu

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02567422
Recruitment Status : Recruiting
First Posted : October 5, 2015
Last Update Posted : September 16, 2021
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 12, 2022
Estimated Study Completion Date : September 12, 2022